Multiomics Tumor Evolution Model of NSCLC

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.

Detailed Description
-----------------
Lung cancer is the leading cause of cancer-related death globally. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and surgery is still the main treatment strategy. This study will determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.

Official Title
-----------------
A Multiomics Study of Tumor Evolution Characteristics and Prognostic Model in Early-stage Non-small Cell Lung Cancer

Conditions
-----------------
Non-small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old; Early-stage NSCLC patients underwent radical surgical resection; Sufficient tumor tissue and blood sample for study use; Available clinical-pathologic data, imaging data and follow-up date; Written informed consent. Exclusion Criteria: History of other malignant tumors; Evidence of distant metastasis before surgery; Insufficient tumor tissue or blood sample for study use; Clinical-pathologic data, imaging data or follow-up date is not available; Other judgments by the Investigator that the patient should not participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Prospective cohort<br>This cohort will enroll a total of 300 patients prospectively | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease-free survival (DFS) | Time from randomization to disease recurrence or death from any cause. | Through study completion, an average of 2 years | 
| Overall survival (OS) | Time from randomization to death from any cause. | Through study completion, an average of 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship between translational biomarkers and clinical outcome | To evaluate if the translational biomarkers can be prediction tools for the clinical outcomes. | Through study completion, an average of 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-small cell lung cancer, Multiomics analysis, Tumor evolution, Tumor immune microenvironment, Circulating tumor DNA, Radiomics, Prognostic model